文献速递血栓与止血

因子IXa和因子X在体外和体内影响因子VIIIa的稳定性和灭活机制

Factor IXa and factor X influence factor VIIIa stability and inactivation mechanisms in vitro and in vivo.
PubMed 文献 · Blood · 2025-01-01

本研究利用重组因子VIIIa变体在生化实验和血友病A小鼠损伤模型中探究A2结构域解离和活化蛋白C(APC)切割对因子VIIIa灭活的影响,发现因子IXa结合可稳定A2结构域并增加APC对因子VIIIa灭活的贡献,而因子IXa和因子X可分别保护Arg562和Arg336位点不被APC切割,且A2结构域稳定化、抑制APC切割或两者联合可分别使促凝效力提高2.4倍、4.8倍和超过10倍。

要点

  • 因子IXa结合稳定因子VIIIa的A2结构域并增加APC对因子VIIIa灭活的贡献。
  • 因子IXa和因子X分别保护Arg562和Arg336位点不被APC切割,但体内保护不完全。
  • 稳定A2结构域、抑制APC切割或两者联合使促凝效力分别提高2.4倍、4.8倍和超过10倍。

核心结论

  • A2结构域解离和APC切割均参与体内因子VIIIa调控,稳定A2结构域、抑制APC切割或两者联合可分别使促凝效力较野生型因子VIII提高2.4倍、4.8倍和超过10倍。
  • 数据支持因子VIIIa灭活两种机制及因子IXa相互作用可用于增强因子VIII功能以获得治疗获益。

研究设计与样本

  • 利用重组因子VIIIa变体在生化实验和血友病A小鼠损伤模型中探究因子VIIIa灭活机制。
  • 重组因子VIIIa变体包括:A2结构域解离探针(FVIIIa-D519V,E665V)、APC切割探针(FVIIIa-R336Q,R562Q)以及两者联合(FVIIIa-R336Q,R562Q/D519V,E665V)。
  • 另用单个APC切割位点变体(FVIIIa-R336Q和FVIIIa-R562Q)进行额外研究。

主要发现

  • 因子IXa结合至因子VIIIa可稳定A2结构域并增加APC对因子VIIIa灭活的贡献。
  • 因子IXa和因子X可分别保护因子VIIIa的Arg562和Arg336位点不被APC切割,但该保护在体内不完全。
  • APC对因子VIIIa的灭活超过对因子VIII的灭活,提示APC对因子VIIIa与因子VIII的识别存在差异。
  • 在小鼠止血实验中,稳定A2结构域、抑制APC切割或两者联合使促凝效力较野生型因子VIII分别提高2.4倍、4.8倍和超过10倍。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Deficiency of factor VIII (FVIII) causes hemophilia A (HA), and excess FVIII function increases venous thromboembolic risk. The phenotypic consequences of aberrant FVIII function underscore the importance of understanding mechanisms that downregulate activated FVIII (FVIIIa) to inform disease pathology and therapeutic drug design. Spontaneous A2-domain dissociation and activated protein C (APC) proteolysis are established mechanisms of FVIIIa inactivation. However, we know very little about how FVIIIa binding interactions with FIXa and FX affect FVIIIa inactivation in vivo. Here, we investigate this using recombinant FVIIIa variants to probe A2-domain dissociation (FVIIIa-D519V,E665V) and APC cleavage (FVIIIa-R336Q,R562Q), or both (FVIIIa-R336Q,R562Q/D519V,E665V), in biochemical assays and in HA mouse injury models. We found that FIXa binding to FVIIIa stabilized the A2 domain and increased the contribution of APC to FVIIIa inactivation. Additional studies using individual APC cleavage site variants (FVIIIa-R336Q and FVIIIa-R562Q) demonstrated that FIXa and FX can protect FVIIIa from APC cleavage at Arg562 and Arg336, respectively, in a manner that is incomplete in vivo. Data also demonstrate that APC inactivation of FVIIIa exceeds FVIII, suggesting differential APC recognition of FVIIIa relative to FVIII. Hemostatic studies of FVIII variants with altered inactivation demonstrated that both A2-domain dissociation and APC cleavage contribute to in vivo FVIIIa regulation. Specifically, stabilizing the A2 domain, inhibiting APC cleavage, or both, improved potency 2.4-, 4.8-, and >10-fold, respectively, over wild-type FVIII in a mouse hemostatic assay. Data support that both mechanisms of FVIIIa inactivation and FIXa interactions could be leveraged to enhance FVIII function for therapeutic benefit.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Morris JJ, Parsons NA, Wilhelm AR, et al. Factor IXa and factor X influence factor VIIIa stability and inactivation mechanisms in vitro and in vivo. Blood. 2025. PMID: 40663775. doi:10.1182/blood.2024027705

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。